Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline

BACKGROUND: This systematic review addresses the question “What is the optimal targeted therapy for female patients with early-stage human epidermal growth factor receptor 2 (her2)–positive breast cancer?” METHODS: The medline and embase databases were searched for the period January 2008 to May 201...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Curr Oncol
Autores principales: Mates, M., Fletcher, G.G., Freedman, O.C., Eisen, A., Gandhi, S., Trudeau, M.E., Dent, S.F.
Formato: Artigo
Lenguaje:Inglês
Publicado: Multimed Inc. 2015
Materias:
Review Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4381787/
https://ncbi.nlm.nih.gov/pubmed/25848335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.22.2322
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares